Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young patients with relapsed or refractory solid tumors or leukemia.
Key facts
- Study ID
- NCT00030108
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 30
- Starts
- 2001-11-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2012-03-15
Who can join
Age: 2 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.